Everest study: Efficacy and safety of verteporfin photodynamic therapy in combination with ranibizumab or alone versus ranibizumab monotherapy in patients with symptomatic macular polypoidal choroidal vasculopathy

Retina

Volumn 32, Issue 8, 2012, Pages 1453-1464

  Koh, Adrian ^a   Lee, Won Ki ^b   Chen, Lee Jen ^c   Chen, Shih Jen ^d,e   Hashad, Yehia ^f   Kim, Hakyoung ^g   Lai, Timothy Y ^h   Pilz, Stefan ⁱ   Ruamviboonsuk, Paisan ^j   Tokaji, Erika ⁱ   Weisberger, Annemarie ⁱ   Lim, Tock H ^k  

^a Camden Medical Centre   (Singapore)

^b The Catholic University of Korea   (South Korea)

^c MACKAY MEMORIAL HOSPITAL   (Taiwan)

^d TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^e NATIONAL YANG MING UNIVERSITY   (Taiwan)

^f ALLERGAN INC   (United States)

^g Hallym University   (South Korea)

^h CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

ⁱ NOVARTIS PHARMA AG   (Switzerland)

^j RAJAVITHI HOSPITAL   (Thailand)

^k TAN TOCK SENG HOSPITAL   (Singapore)

more..

Author keywords

angio occlusion; confocal scanning laser ophthalmoscope; indocyanine green angiography; polyp regression; polypoidalchoroidal vasculopathy; ranibizumab; verteporfin PDT

Indexed keywords

RANIBIZUMAB; VERTEPORFIN;

ADULT; ANGINA PECTORIS; ARTICLE; ASIAN; ASTHENOPIA; BILIARY TRACT INFECTION; CONJUNCTIVAL HEMORRHAGE; CONJUNCTIVAL HYPEREMIA; CONTROLLED STUDY; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRY EYE; FEMALE; HUMAN; HYPERTENSION; INDOCYANINE GREEN ANGIOGRAPHY; INTRAOCULAR HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTICENTER STUDY; NONCARDIAC CHEST PAIN; PHASE 4 CLINICAL TRIAL; PHOTODYNAMIC THERAPY; POLYPOIDAL CHOROIDAL VASCULOPATHY; RANDOMIZED CONTROLLED TRIAL; REMISSION; RETINA HEMORRHAGE; RETINA MACULA EDEMA; RHINOPHARYNGITIS; SCAR; SHAM PROCEDURE; STOMACH CANCER; UPPER RESPIRATORY TRACT INFECTION; VISUAL ACUITY; VISUAL IMPAIRMENT; VITREOUS HEMORRHAGE;

AGED; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; CHOROID; CHOROID DISEASES; COLORING AGENTS; COMBINED MODALITY THERAPY; DOUBLE-BLIND METHOD; FEMALE; FLUORESCEIN ANGIOGRAPHY; HUMANS; INDOCYANINE GREEN; INTRAVITREAL INJECTIONS; MALE; MIDDLE AGED; PHOTOCHEMOTHERAPY; PHOTOSENSITIZING AGENTS; POLYPS; PORPHYRINS; TREATMENT OUTCOME; VISUAL ACUITY;

EID: 84865721295     PISSN: 0275004X     EISSN: 15392864     Source Type: Journal    
DOI: 10.1097/IAE.0b013e31824f91e8     Document Type: Article

References (30)

1. Yannuzzi LA, Ciardella A, Spaide RF, et al. The expanding clinical spectrum of idiopathic polypoidal choroidal vasculopathy. Arch Ophthalmol 1997;115:478-485. (Pubitemid 27172703)
2. Kwok AK, Lai TY, Chan CW, et al. Polypoidal choroidal vasculopathy in Chinese patients. Br J Ophthalmol 2002;86:892-897. (Pubitemid 34827970)
3. Sho K, Takahashi K, Yamada H, et al. Polypoidal choroidal vasculopathy: incidence, demographic features, and clinical characteristics. Arch Ophthalmol 2003;121:1392-1396. (Pubitemid 37243739)
4. Obata R, Yanagi Y, Kami J, et al. Polypoidal choroidal vasculopathy and retinichoroidal anastomosis in Japanese patients eligible for photodynamic therapy for exudative age related macular degeneration. Jpn J Ophthalmol 2006;50:354-360. (Pubitemid 44167444)
5. Chen SJ, Cheng CY, Peng KL, et al. Prevalence and associated risk factors of age-related macular degeneration in an elderly Chinese population in Taiwan: the Shihpai Eye Study. Invest Ophthalmol Vis Sci 2008;49:3126-3133.
6. Uyama M, Wada M, Nagai Y, et al. Polypoidal choroidal vasculopathy: natural history. Am J Ophthalmol 2002;133:639-648. (Pubitemid 34462012)
7. Yuzawa M, Mori R, Kawamura A. The origins of polypoidal choroidal vasculopathy. Br J Ophthalmol 2005;89:602-607. (Pubitemid 40569719)
8. Shiraga F, Matsuo T, Yokoe S, et al. Surgical treatment of submacular hemorrhage associated with idiopathic polypoidal choroidal vasculopathy. Am J Ophthalmol 1999;128:147-154. (Pubitemid 29379766)
9. Yoon JS, Lee J, Lee SC, et al. Polypoidal choroidal vasculopathy in Korean patients with large submacular hemorrhage. Yonsei Med J 2007;48:225-232. (Pubitemid 46711752)
10. Tsuchiya D, Yamamoto T, Kawasaki R, Yamashita H. Twoyear outcomes after photodynamic therapy in age-related macular degeneration patients with or without polypoidal choroidal vasculopathy lesions. Retina 2009;29:960-965.
11. Akaza E, Mori R, Yuzawa M. Long-term results of photodynamic therapy of polypoidal choroidal vasculopathy. Retina 2008;28:717-722. (Pubitemid 351655124)
12. Gomi F, Ohji M, Sayanagi K, et al. One-year outcomes of photodynamic therapy in age-related macular degeneration and polypoidal choroidal vasculopathy in Japanese patients. Ophthalmology 2008;115:141-146. (Pubitemid 350309415)
13. Hirami Y, Tsujikawa A, Kameda T, et al. Hemorrhagic complications after photodynamic therapy for polypoidal choroidal vasculopathy. Retina 2007;27:335-341. (Pubitemid 46398898)
14. Mauget-Faysse M, Quaranta-El Maftouhi M, De La ME, Leys A. Photodynamic therapy with verteporfin in the treatment of exudative idiopathic polypoidal choroidal vasculopathy. Eur J Ophthalmol 2006;16:695-704. (Pubitemid 44870751)
15. Silva RM, Figueira J, Cachulo ML, et al. Polypoidal choroidal vasculopathy and photodynamic therapy with verteporfin. Graefes Arch Clin Exp Ophthalmol 2005;243:973-979. (Pubitemid 41631036)
16. Chan WM, Lam DSC, Lai TY, et al. Photodynamic therapy with verteporfin for symptomatic polypoidal choroidal vasculopathy. One-year results of a prospective case series. Ophthalmology 2004;111:1576-1584. (Pubitemid 39030815)
17. Quaranta M, Mauget-Faÿsse M, Coscas G. Exudative idiopathic polypoidal choroidal vasculopathy and photodynamic therapy with verteporfin. Am J Ophthalmol 2002;134:277-280. (Pubitemid 34831840)
18. Spaide RF, Donsoff I, Lam DL, et al. Treatment of polypoidal choroidal vasculopathy with photodynamic therapy. Retina 2002;22:529-535. (Pubitemid 35176066)
19. Tong JP, Chan WM, Liu DT, et al. Aqueous humor levels of vascular endothelial growth factor and pigment epithelium-derived factor in polypoidal choroidal vasculopathy and choroidal neovascularization. Am J Ophthalmol 2006;14:456-462. (Pubitemid 43265948)
20. Lai TY, Chan WM, Liu DT, et al. Intravitreal bevacizumab (Avastin) with or without photodynamic therapy for the treatment of polypoidal choroidal vasculopathy. Br J Ophthalmol 2008;92:661-666. (Pubitemid 351684177)
21. Gomi F, Sawa M, Sakaguchi H, et al. Efficacy of intravitreal bevacizumab for polypoidal choroidal vasculopathy. Br J Ophthalmol 2008;92:70-73.
22. Cheng CK, Peng CH, Chang CK, et al. One-year outcomes of intravitreal bevacizumab (avastin) therapy for polypoidal choroidal vasculopathy. Retina 2011;31:846-856.
23. Kokame GT, Yeung L, Lai JC. Continuous anti-VEGF treatment with ranibizumab for polypoidal choroidal vasculopathy: 6-month results. Br J Ophthalmol 2010;94:297-301.
24. Lai TY, Lee GK, Luk FO, Lam DS. Intravitreal ranibizumab with or without photodynamic therapy for the treatment of symptomatic polypoidal choroidal vasculopathy. Retina 2011;31: 1581-1588.
25. Blinder KJ, Bradley S, Bressler NM, et al. Effect of lesion size, visual acuity, and lesion composition on visual acuity change with and without verteporfin therapy for choroidal neovascularization secondary to age-related macular degeneration: TAP and VIP report no. 1. Am J Ophthalmol 2003; 136:407-418. (Pubitemid 37101236)
26. Chung SE, Kang SW, Lee JH, Kim YT. Choroidal thickness in polypoidal choroidal vasculopathy and exudative age-related macular degeneration. Ophthalmology 2011;118: 840-845.
27. Maruko I, Iida T, Sugano Y, et al. Subfoveal retinal and choroidal thickness after verteporfin photodynamic therapy for polypoidal choroidal vasculopathy. Am J Ophthalmol 2011; 151:594-603.e1.
28. Wakabayashi T, Gomi F, Sawa M, et al. Intravitreal bevacizumab for exudative branching vascular networks in polypoidal choroidal vasculopathy. Br J Ophthalmol 2012;96:394-399.
29. Kim KS, Lee WK. Bevacizumab for serous changes originating from a persistent branching vascular network following photodynamic therapy for polypoidal choroidal vasculopathy. Jpn J Ophthalmol 2011;55(4):370-377.
30. Saito M, Iida T, Kano M. Intravitreal ranibizumab for polypoidal choroidal vasculopathy with recurrent or residual exudation. Retina 2011;31(8):1589-1597.